SLC5A2 and diabetic kidney disease: Intensive treatments on clinical risk factors and administration of kidney protective agents such as renin-angiotensin system (RAS) blockers, sodium- glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists may favourably alter the trajectory of DKD progression.